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AbstrACt
Objectives To compare the prevalence of different 
insomnia subtypes among middle- aged adults from 
Europe and Australia and to explore the cross- sectional 
relationship between insomnia subtypes, respiratory 
symptoms and lung function.
Design Cross- sectional population- based, multicentre 
cohort study.
setting 23 centres in 10 European countries and 
Australia.
Methods We included 5800 participants in the third 
follow- up of the European Community Respiratory Health 
Survey III (ECRHS III) who answered three questions on 
insomnia symptoms: difficulties falling asleep (initial 
insomnia), waking up often during the night (middle 
insomnia) and waking up early in the morning and not 
being able to fall back asleep (late insomnia). They also 
answered questions on smoking, general health and 
chronic diseases and had the following lung function 
measurements: forced expiratory volume in 1 s (FEV
1), 
forced vital capacity (FVC) and the FEV1/FVC ratio. Changes 
in lung function since ECRHS I about 20 years earlier were 
also analysed.
Main outcome measures Prevalence of insomnia 
subtypes and relationship to respiratory symptoms and 
function.
results Overall, middle insomnia (31.2%) was the most 
common subtype followed by late insomnia (14.2%) and 
initial insomnia (11.2%). The highest reported prevalence 
of middle insomnia was found in Iceland (37.2%) and 
the lowest in Australia (22.7%), while the prevalence of 
initial and late insomnia was highest in Spain (16.0% 
and 19.7%, respectively) and lowest in Denmark (4.6% 
and 9.2%, respectively). All subtypes of insomnia were 
associated with significantly higher reported prevalence of 
respiratory symptoms. Only isolated initial insomnia was 
associated with lower FEV
1, whereas no association was 
found between insomnia and low FEV1/FVC ratio or decline 
in lung function.
Conclusion There is considerable geographical variation 
in the prevalence of insomnia symptoms. Middle insomnia 
is most common especially in Iceland. Initial and late 
insomnia are most common in Spain. All insomnia 
subtypes are associated with respiratory symptoms, and 
initial insomnia is also associated with lower FEV1.
IntrODuCtIOn
A good night’s sleep is vital for daily func-
tioning, general health and well- being.1 Sleep 
disturbances are highly prevalent in the 
general population and often have consider-
able impact on health and quality of life.2–4 
Insomnia is categorised as difficulty falling 
asleep (initial insomnia), waking up often 
during the night (middle insomnia) and 
waking up too early in the morning (late 
insomnia).
Insomnia is common and is associated with 
various negative consequences for health 
and well- being.5 Previous studies have shown 
geographical variation in prevalence of sleep 
disturbances. Léger et al6 reported sleep 
disturbances, including insomnia occurring 
in 6.6%–37% in four countries (France, 
strengths and limitations of this study
 ► The strengths of this study include the population- 
based nature of this large sample collected in 
the same manner at many centres in 11 different 
countries.
 ► Another strength is the use of standardised and val-
idated procedures and instruments.
 ► One limitation of our study is the cross- sectional 
study design that cannot tell us the direction of the 
association found since the underlying causal path-
ways can only be obtained from longitudinal or in-
tervention studies.
 ► Another limitation is the fact that we only have infor-
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Figure 1 The number of subjects with different insomnia 
subtypes and the number with isolated insomnia subtypes in 
the random sample (n=5043).
Figure 2 The prevalence of the different insomnia subtypes 
in the different countries.
Table 1 Characteristics of the participants in ECRHS III 







Age 53.7±7.2 55.2±6.9 <0.0001
Women 48.0 59.6 <0.0001
BMI 27.0±4.7 27.5±5.2 0.0002
BMI groups     0.003
  <20 3.3 3.0
  20–25 33.9 31.7
  >25–30 40.7 38.7
  >30 22.1 26.6
Smoking 
history
    0.04
  Never 45.2 42.2
  Ex 36.3 39.4
  Current 18.5 18.4
Pack years 10.8±17.7 12.7±21.3 0.0003
Insomnia symptom refers to individuals who have symptoms of 
either initial, middle or late insomnia ≥3×/week.
BMI, body mass index; ECRHS III, European Community 
Respiratory Health Survey III.
Italy, Japan and USA). Previous studies conducted in 
Sweden, Iceland Belgium, Great Britain, Germany and 
Ireland found the prevalence rates of insomnia to range 
from 4% to 22%.7 8 Furthermore, a study by Dregan and 
Armstrong9 comparing sleep disturbances and their 
relationship to age among subjects from 23 European 
countries found substantial differences in sleep patterns 
across these countries. A similar result was obtained in a 
recent study of older European adults.10 However, these 
studies used a single item measure of sleep disturbances 
and could therefore not evaluate different subtypes of 
insomnia.
Several studies have shown associations between 
insomnia and respiratory symptoms.11–14 Having 
asthma has been associated with a higher prevalence 
of insomnia,15 16 and patients with chronic obstructive 
pulmonary disease (COPD) commonly report disturbed 
sleep, including symptoms of insomnia.17 There is, 
however, a lack of large epidemiological studies exploring 
the association between different insomnia subtypes and 
respiratory symptoms and between insomnia and lung 
function using standardised methodology in a large 
number of countries.
The aim of the present study was to compare the prev-
alence of different insomnia subtypes among middle- 
aged subjects from 23 centres in 11 countries as well 
as exploring the relationship of different subtypes of 
insomnia with respiratory symptoms and lung function.
MAterIAl AnD MethODs
subjects
We studied participants in the third follow- up of the Euro-
pean Community Respiratory Health Survey III (ECRHS 
III; www. ecrsh. org), an international, population- based, 
multicentre cohort study of asthma and allergy, which 
was first performed in 1990. Detailed descriptions of the 
methods for ECRHS I and ECRHS II have been published 
elsewhere.18 19 Briefly, participating centres first randomly 
selected samples of 20–44 year old subjects. Participants 
completed a short postal questionnaire about asthma and 
asthma- like symptoms, and from those who responded, a 
random sample was selected to undergo a more detailed 
clinical examination. In addition, a ‘symptomatic sample’ 
reporting symptoms of waking with shortness of breath, 
asthma attacks or using asthma medication in stage 1 was 
also studied. In ECRHS II, subjects who had participated 
in the clinical phase of ECRHS I were invited to partici-
pate in the follow- up. The clinical phase of ECRHS I and 
II was performed between 1991–1994 and 1998–2002, 
respectively. ECRHS III is the second follow- up and was 
performed from February 2011 to January 2014.19 20 The 
present study is based on data from ECRHS III except for 
 on D
ecem









pen: first published as 10.1136/bm





3Bjornsdottir E, et al. BMJ Open 2020;10:e032511. doi:10.1136/bmjopen-2019-032511
Open access
Table 2 Association between the number of insomnia symptoms, lung function and respiratory symptoms in adults from 














  Wheeze 21.3 26.9 29.3 36.3 <0.0001
  Nocturnal chest tightness 11.0 17.3 21.2 29.3 <0.0001
  Breathless ness at rest 5.8 7.4 10.4 18.3 <0.0001
  Breathlessness after effort 19.3 26.6 28.7 36.5 <0.0001
  Nocturnal breathlessness 6.4 8.9 12.6 18.8 <0.0001
  Nocturnal cough 28.1 35.0 40.2 46.8 <0.0001
  Morning cough 9.8 12.9 17.0 18.3 <0.0001
  Morning phlegm 11.8 13.6 19.4 19.4 <0.0001
Lung function
FEV1 (% pred) pre 95.4±14.6 93.9±14.8 93.6±15.2 92.8±16.3 0.0004
FVC (% pred) pre 99.4±13.3 98.3±13.7 98.4±14.3 98.3±14.5 0.046
FEV1
/FVC pre 0.76±0.06 0.76±0.07 0.75±0.07 0.75±0.07 0.008
FEV1 (% pred) post 97.7±14.2 96.6±14.2 96.0±14.9 96.0±15.5 0.02
FVC (% pred) post 98.6±13.0 98.1±12.9 97.9±13.7 98.0±14.0 0.49
FEV1/FVC post 0.78±0.06 0.78±0.07 0.78±0.07 0.77±0.07 0.06
Change in FEV1 pre (% pred) −4.5±10.1 −5.5±10.8 −5.8±10.1 −5.3±11.6 0.01
Change in FVC pre (% pred) −0.89±9.2 −1.9±10.1 −1.8±9.9 −0.53±10.4 0.01
Insomnia symptom refers to individuals who have symptoms of either initial, middle or late insomnia ≥3×/week.
ECRHS III, European Community Respiratory Health Survey III; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
change in lung function which shows the change from 
ECRHS I- III (see below).
Questionnaires and measurements
Subjects answered the core ECRHS questionnaires that 
included questions on respiratory symptoms and smoking 
history. The following respiratory symptoms were 
assessed: wheeze, nocturnal chest tightness or attacks of 
breathlessness following activity, at rest or at night during 
and attacks of nocturnal cough the last 12 months as well 
as usually having to cough in the morning and usually 
bringing up phlegm in the morning.
Sleep- related symptoms were assessed by using the 
Basic Nordic Sleep Questionnaire,21 where participants 
were asked about frequency of insomnia symptoms. 
Answers were on a scale of 1–5: (1) never or very seldom, 
(2) less than once a week, (3) once to twice a week, (4) 
three to five times a week and (5) every day or almost 
every day of the week. Insomnia symptoms were defined 
using answers to three questions from the BSNQ: ‘I have 
difficulties falling asleep at night’ (initial insomnia), 
‘I wake up often during the night’ (middle insomnia) 
and ‘I wake up early in the morning and can’t fall back 
asleep’ (late insomnia). Those who reported those symp-
toms of insomnia ≥3 times a week (scores 4 and 5) were 
considered to have the appropriate subtype. At ECRHS 
III, forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC) were recorded prebronchodi-
lation and postbronchodilation with 200 µg salbutamol, 
using the EasyOne NDD spirometer. All subjects made 
at least five forced expiratory manoeuvres, and maximal 
values with up to 150 mL reproducibility were used for 
analysis. Predicted values were calculated using data from 
the Global Lung function Initiative.22 In ECRHS I and 
II, spirometry data were recorded similarly, but no bron-
chodilation was performed. Change in prebronchodila-
tory lung function from ECRHS I to III was calculated as 
change in % of predicted between the surveys.
Height and weight were measured at the time of the 
spirometry, and body mass index (BMI) was calculated
Patient and public involvement
Patients and public were not involved in the designing 
process of this study. The purpose of this research was 
introduced to all participating patients, and informed 
consents were sought from all the participants. All partic-
ipants completed this survey on the voluntary basis. No 
patient was asked for advice on interpretation or writing 
up of results. The results of the research will not be 
disseminated to the patients.
statistics
Data are presented as number and percentage or 
mean±SD, depending on distribution. The random 
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Wheeze 21.3 35.0 <0.0001 24.8 0.02 29.6 0.004
Nocturnal chest tightness 11.0 24.6 <0.0001 15.9 <0.0001 17.4 0.005
Breathlessness at rest 5.8 10.7 0.008 6.7 0.31 7.4 0.34
Breathlessness after effort 19.3 34.3 <0.0001 25.5 <0.0001 25.6 0.03
Nocturnal breathlessness 6.4 10.9 0.02 7.7 0.13 12.3 0.001
Nocturnal cough 28.1 36.3 0.02 34.2 <0.0001 37.6 0.003
Morning cough 9.8 14.4 0.046 12.0 0.04 15.4 0.008
Morning phlegm 11.8 16.3 0.07 12.6 0.52 16.4 0.048
Lung function
FEV1 (% pred) pre 95.4±14.6 91.7±14.4 0.002 94.4±14.6 0.06 93.4±15.4 0.06
FVC (% pred) pre 99.4±13.3 96.2±14.6 0.004 98.6±13.5 0.11 98.3±13.6 0.28
FEV1/FVC pre 0.76±0.06 0.76±0.06 0.99 0.76±0.07 0.29 0.75±0.07 0.04
FEV1 (% pred) post 97.7±14.2 94.4±14.5 0.005 97.1±14.1 0.33 96.4±14.5 0.24
FVC (% pred) post 98.6±13.0 96.6±12.4 0.06 98.3±13.0 0.55 98.3±13.1 0.72
FEV1/FVC post 0.78±0.06 0.78±0.07 0.34 0.78±0.07 0.56 0.78±0.06 0.19
Change in FEV1 pre (% pred) −4.5±10.1 −5.7±9.9 0.18 −5.3±10.9 0.052 −6.2±11.0 0.04
Change in FVC pre (% pred) −0.89±9.2 −1.7±11.7 0.29 −1.8±10.0 0.02 −2.5±9.4 0.03
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
sample from ECRHS III was used when comparing preva-
lence between participants from different countries. The 
whole sample (random and symptomatic) was used for all 
other analyses as our aim in these analyses was to examine 
associations with respiratory symptoms and lung function 
and not to estimate incidence rates or prevalence in a 
representative population. For bivariate analysis, the χ2 
test, t- test and one- way analysis of variance were used for 
nominal and continuous variables. Logistic regression 
was used for multivariable analyses to estimate the asso-
ciation between insomnia and respiratory symptoms after 
adjusting for potential confounders such as sex, age, BMI 
and smoking status. In a previous study in the same popu-
lation, we found associations between nocturnal gastro- 
oesophageal reflux and respiratory symptoms, while 
habitual snoring was independently associated with both 
symptoms and lung function.23 We therefore performed 
a sensitivity analyses including nocturnal gastro- 
oesophageal reflux and snoring in the multivariable anal-
yses. STATA V.15 was used for all statistical analyses.
results
Geographical variation
Data from 23 centres and 11 countries were gathered. Of 
the participants, 5043 were from the random sample.19 
The overall prevalence of any insomnia symptom was 
39.4%. Middle insomnia (31.3%) was the most common 
subtype followed by late insomnia (15.3%) and initial 
insomnia (11.3%) (figure 1). There was a consider-
able overlap between the three subtypes of insomnia 
(figure 1).
The highest prevalence of middle insomnia was found 
in Iceland and the lowest in Australia, while the preva-
lence of initial insomnia and late insomnia was highest 
in Spain and lowest in Denmark. The pattern of the prev-
alence of different subtypes was consistent across coun-
tries with initial insomnia being less common than late 
insomnia and middle insomnia being the most common 
subtype (figure 2).
respiratory symptoms and lung function
After including the symptomatic sample, a total of 5800 
subjects were included in the analysis. The characteristics 
of participants with or without insomnia symptoms are 
presented in table 1. Subjects reporting insomnia symp-
toms were more often women, older, more likely to be 
ex- smokers and had a higher BMI.
The prevalence of most respiratory symptoms increased 
with the number of insomnia symptoms (table 2). There 
was also a significant association between lung function and 
insomnia symptoms for most of the lung function variables.
The association between isolated insomnia subtypes 
and lung function and respiratory symptoms is presented 
in table 3. All three subtypes were associated with a higher 
prevalence of most respiratory symptoms. Isolated initial 
insomnia was significantly associated with a low prebron-
chodilator and postbronchodilator FEV1 and a low 
prebronchodilator FVC (table 3).
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Table 4 Independent association between number of insomnia symptoms and also between the isolated insomnia subtypes 
















Respiratory symptom* OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
  Wheeze 1.37 (1.17 to 
1.61)
1.42 (1.13 to 
1.79)
2.13 (1.60 to 
2.83)
1.66 (1.15 to 
2.40)
1.27 (1.05 to 
1.53)
1.54 (1.20 to 
2.16)
  Nocturnal chest 
tightness
1.68 (1.38 to 
2.04)
2.11 (1.63 to 
2.73)
3.27 (2.41 to 
4.43)
2.15 (1.43 to 
3.23)
1.63 (1.30 to 
2.05)
1.55 (1.03 to 
2.33)
  Breathlessness at rest 1.30 (0.99 to 
1.72)
1.91 (1.36 to 
2.68)
3.15 (2.18 to 
4.55)
1.66 (0.96 to 
2.88)
1.23 (0.89 to 
1.70)
1.14 (0.63 to 
2.05)
  Breathlessness after 
effort
1.47 (1.24 to 
1.74)
1.66 (1.31 to 
2.10)
2.45 (1.84 to 
3.26)
1.80 (1.23 to 
2.63)
1.39 (1.14 to 
1.69)
1.44 (0.995 to 
2.08)
  Nocturnal 
breathlessness
1.51 (1.17 to 
1.95)
2.31 (1.68 to 
3.18)
3.33 (2.33 to 
4.76)
1.59 (0.91 to 
2.78)
1.36 (1.01 to 
1.85)
1.87 (1.17 to 
2.99)
  Nocturnal cough 1.31 (1.13 to 
1.52)
1.67 (1.36 to 
2.05)
1.92 (1.48 to 
2.51)
1.22 (0.85 to 
1.73)
1.27 (1.07 to 
1.51)
1.53 (1.11 to 
2.11)
  Morning cough 1.53 (1.24 to 
1.89)
2.09 (1.59 to 
2.73)
2.12 (1.50 to 
2.98)
1.53 (0.96 to 
2.44)
1.51 (1.18 to 
1.93)
1.66 (1.70 to 
2.55)
  Morning phlegm 1.17 (0.96 to 
1.44)
1.89 (1.46 to 
2.44)
1.73 (1.24 to 
2.42)
1.10 (0.69 to 
1.77)
1.15 (0.91 to 
1,46)
1.30 (0.86 to 
1.99)
Lung function* Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI)
FEV1 (% pred) pre −1.04 (−2.02 
to −0.06)
−1.02 (−2.42 to 
0.38)




−0.57 (−1.68 to 
0.53)
−1.38 (−3.50 to 
0.82)
FVC (% pred) pre −0.68 (−1.57 
to 0.22)
−0.40 (−1.69 to 
0.88)




−0.24 (−1.24 to 
0.76)
−0.57 (−2.53 to 
1.39)
FEV1/FVC pre −0.00 (−0.01 
to 0.003)
−0.01 (−0.01 to 
0.000)
−0.01 (−0.01 to 
0.001)
0.00 (−0.01 to 
0.01)
−0.00 (−0.01 to 
0.003)
−0.01 (−0.02 to 
0.001)
FEV1 (% pred) post −0.64 (−1.60 
to 0.32)
−0.96 (−2.35 to 
0.43)




−0.24 (−1.31 to 
0.84)
−0.62 (−2.73 to 
1.49)
FVC (% pred) post −0.30 (−1.18 
to 0.59)
−0.23 (−1.51 to 
1.5)




0.00 (−1.00 to 
0.99)
0.06 (−1.88 to 
2.01)
FEV1/FVC post −0.00 (0.01 to 
0.003)
−0.00 (−0.01 to 
0.001)




0.00 (−0.005 to 
0.005)
−0.01 (−0.01 to 
0.004)




−0.55 (−1.53 to 
0.43)




−0.09 (−0.86 to 
0.68)
−1.12 (−2.58 to 
0.35)




−0.63 (−1.53 to 
0.27)




−0.29 (−0.99 to 
0.40)
−0.90 (−2.22 to 
0.42)
Statistically significant associations are marked as bold. The reference group are subjects without insomnia symptoms.
*Adjusted for age, sex, BMI, pack years and centre.
†In addition to above also adjusted for change in BMI between ECRHS I and III.
BMI, body mass index; ECRHS, European Community Respiratory Health Survey; FEV1, forced expiratory volume in 1 s; FVC, forced vital 
capacity.
Multiple variable analyses
There was a clear independent association between the 
number of insomnia symptoms and all respiratory symp-
toms, whereas there was no association to lung function 
or decline in lung function after adjustment for age, sex, 
BMI and smoking (table 4). All three subtypes of insomnia 
were associated with most of the respiratory symptoms. 
Isolated early insomnia was independently associated with 
both prebronchodilatory and postbronchodilatory FEV1, 
whereas no association to FEV1/FVC ratio or decline of 
lung function as measured as prebronchodilator was 
found for any of the insomnia subtypes. Most associa-
tions remained statistically significant also after including 
nocturnal gastro- oesophageal reflux and habitual snoring 
in the model (table 5).
DIsCussIOn
In the present study, almost one out of three subjects had 
symptoms of middle insomnia, 14% had late insomnia and 
11% initial insomnia. We have reported such high prev-
alence of middle insomnia (especially related to obstruc-
tive sleep apnoea),13 while other general population 
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Table 5 Independent association between number of insomnia symptoms and also between the isolated insomnia subtypes 













Respiratory symptom* OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
  Wheeze 1.29 (1.07 to 
1.56)
1.22 (0.93 to 
1.56)
1.83 (1.30 to 
2.56)
1.26 (0.80 to 2.00) 1.24 (0.997 to 
1.54)
1.49 (0.97 to 
2.24)
  Nocturnal chest 
tightness
1.54 (1.21 to 
1.95)
2.07 (1.52 to 
2.83)
2.81 (1.92 to 
4.10)
1.94 (1.16 to 
3.22)
1.53 (1.16 to 
2.01)
1.39 (0.82 to 
2.35)
  Breathlessness at rest 1.32 (0.93 to 
1.87)
2.20 (1.46 to 
3.32)
3.73 (2.37 to 
5.87)
1.55 (0.74 to 3.24) 1.19 (0.79 to 
1.79)
1.46 (0.72 to 
2.94)
  Breathlessness after 
effort
1.50 (1.23 to 
1.83)
1.62 (1.23 to 
2.13)
2.19 (1.55 to 
3.09)
1.99 (1.28 to 
3.10)
1.43 (1.15 to 
1.79)
1.37 (0.85 to 
2.11)
  Nocturnal 
breathlessness
1.33 (0.96 to 
1.84)
2.01 (1.34 to 
3.02)
3.29 (2.10 to 
5.16)
0.99 (0.43 to 2.27) 1.22 (0.83 to 
1.79)
2.03 (1.11 to 
3.70)
  Nocturnal cough 1.23 (1.04 to 
1.45)
1.46 (1.16 to 
1.84)
1.76 (1.29 to 
2.39)
1.15 (0.77 to 1.74) 1.21 (1.001 to 
1.46)
1.45 (0.63 to 
2.38)
  Morning cough 1.51 (1.18 to 
1.92)
1.91 (1.39 to 
2.61)
2.06 (1.38 to 
3.07)
1.40 (0.80 to 2.46) 1.54 (1.17 to 
2.04)
1.59 (0.95 to 
2.68)
  Morning phlegm 1.15 (0.91 to 
1.45)
1.68 (1.25 to 
2.26)
1.49 (0.99 to 
2.24)
1.20 (0.70 to 2.06) 1.17 (0.90 to 
1.53)
1.06 (0.62 to 
1.80)
Lung function* Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI) Beta (95% CI)
FEV1 (% pred) pre −0.87 (−1.92 to 
0.19)
−0.86 (−2.37 to 
0.64)
−2.04 (−4.08 to 
−0.01)
−3.33 (−5.94 to 
−0.72)
−0.57 (−1.74 to 
0.61)
0.24 (−2.14 to 
2.62)
FVC (% pred) pre −0.42 (−1.41 to 
0.57)
−0.25 (−1.67 to 
1.16)
−0.85 (−2.76 to 
1.07)
−2.48 (−4.91 to 
−0.04)
−0.20 (−1.29 to 
0.90)
0.88 (−1.35 to 
3.11)
FEV1/FVC pre −0.00 (−0.01 to 
0.002)
−0.01 (−0.01 to 
0.001)
−0.01 (−0.02 to 
−0.001)
0.00 (−0.01 to 
0.01)
−0.00 (−0.01 to 
0.002)
−0.01 (−0.02 to 
0.004)
FEV1 (% pred) post −0.66 (−1.70 to 
0.38)
−0.82 (−2.33 to 
0.69)
−1.73 (−3.75 to 
0.28)
−2.77 (−5.29 to 
−0.25)
−0.37 (−1.52 to 
0.79)
0.37 (−1.97 to 
2.72)
FVC (% pred) post −0.27 (−1.24 to 
0.70)
−0.10 (−1.51 to 
1.32)
−0.41 (−2.28 to 
1.47)
−1.47 (−3.84 to 
0.90)
−0.13 (−1.21 to 
0.96)
0.84 (−1.36 to 
3.03)
FEV1/FVC post −0.00 (0.01 to 
0.003)
−0.01 (−0.01 to 
0.001)
−0.01 (−0.02 to 
-0.001)
−0.01 (−0.02 to 
0.005)
0.00 (−0.005 to 
0.005)
−0.01 (−0.02 to 
0.01)
Change in FEV1 pre
(% pred)†
−0.12 (−0.90 to 
0.47)
−0.64 (−1.68 to 
0.40)
1.09 (−0.38 to 
0.40)
0.29 (−1.49 to 
2.07)
−0.03 (−0.84 to 
0.79)
−1.05 (−2.65 to 
0.56)
Change in FVC pre (% 
pred)†
−0.30 (−0.98 to 
0.38)
−0.84 (−1.81 to 
0.13)
0.95 (−0.40 to 
2.30)
−0.05 (−1.72 to 
1.62)
−0.38 (−1.13 to 
0.37)
−0.12 (−1.60 to 
1.37)
Statistically significant associations are marked as bold. The reference group are subjects without insomnia symptoms.
*Adjusted for age, sex, BMI, pack years, nocturnal gastro- oesophageal reflux, habitual snoring and centre.
†In addition to above also adjusted for change in BMI between ECRHS I and III.
BMI, body mass index; ECRHS, European Community Respiratory Health Survey; FEV1, forced expiratory volume in 1 s; FVC, forced 
vital capacity.
based studies have not found middle insomnia to be the 
most prevalent subtype.24 All subtypes of insomnia were 
related to an increased prevalence of respiratory symp-
toms, and having initial insomnia was also related to 
lower lung function. The prevalence of middle insomnia 
was highest in Iceland, whereas the prevalence of early 
and late insomnia was highest in Spain.
Others studies have not compared the prevalence of 
insomnia subtypes between different countries in Europe 
and Australia, but they have however also reported 
geographical differences in sleep disorders.6–10 In our 
previous analyses of these data as used in this one,19 we 
found considerable differences in sleep duration between 
centres, and the highest percentage of short sleepers 
were in the Spanish centres. In the current study, we 
also found a trend in Spain where both initial and late 
insomnia subtypes are most common there. These differ-
ences might be explained by cultural differences, working 
hours, unemployment and other social or economic 
factors, but we lack comparative data to study that further.
In the present study, we found an independent associa-
tion between insomnia symptoms and respiratory symp-
toms. An association between insomnia and respiratory 
disorders such as asthma and COPD have been reported in 
previous studies,11 14 25 but to our knowledge, no data exist 
on the association between different insomnia subtypes and 
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respiratory symptoms. A possible explanation for an associ-
ation between poor respiratory health and insomnia could 
be some abnormal ventilatory mechanics and/or nocturnal 
respiratory symptoms such as cough and/or breathing diffi-
culties.26 Within the rich ECRHS data set, we hope to be 
able to enlighten the ‘whole picture’ further by also eval-
uating the possible role of physical activity, worse general 
health and impaired quality of life among subjects with 
both insomnia and respiratory symptoms.
In accordance with previous studies, participants with 
insomnia symptoms in the present study had a higher 
BMI than subjects without insomnia.27 28 Obesity is also 
related to other disorders that influence sleep such as 
nocturnal gastroesophageal reflux (nGER) and obstruc-
tive sleep apnoea. The association between respiratory 
and insomnia symptoms remained significant also after 
adjusting for nocturnal gastro- oesophageal reflux and 
snoring. It further strengthens an independent associa-
tion between insomnia and respiratory symptoms.
In the present study, we found that having isolated early 
insomnia was associated with lower FEV1. In a study by 
Budhiraja et al,17 FEV1 was the same among participants 
with insomnia compared with those without insomnia. 
Different insomnia subtypes were, however, not explored 
in their study. We did not find any significant associa-
tion between insomnia symptoms and airflow obstruc-
tion (FEV1/FVC) or decline in lung function, but it is 
important to note that most subject in our sample had 
FEV1 within the normal range. These results are in line 
with the study of Budhiraja et al,17 although others have 
found an association of COPD- related variables with 
insomnia severity.29 Due to these conflicting results and 
a lack of data regarding this, further studies are needed 
on this topic. There are several limitations of this study 
that need to be considered. Our results are from a cross- 
sectional study, and deeper understanding of the direc-
tion of the association of underlying causal pathways 
can only be obtained from longitudinal or intervention 
studies. The questions used to assess insomnia can only 
provide information on insomnia symptoms, but we do 
not have enough information to make an insomnia diag-
nosis. Another limitation is that we have information 
about respiratory symptoms, but the occurrence of respi-
ratory illness was not confirmed. The data on geograph-
ical variation were only obtained from a limited number 
of subjects from each country. The strengths of this study 
include the population- based nature of this large sample 
collected in the same manner at many centres in 11 
different countries and the use of standardised and vali-
dated procedures and instruments.
Considering the prevalence and negative health conse-
quences of both insomnia and respiratory disorders in 
general, these results have important clinical and public 
health implications. Having in mind that there is a 2–3 
fold increase of reported insomnia among those with 
respiratory symptoms, both insomnia and respiratory 
symptoms should be kept in mind when either one is 
presented clinically. Prospective longitudinal studies 
need to be designed to ascertain the causality of the asso-
ciation between insomnia and respiratory symptoms. 
The traditional view is that poorly controlled respiratory 
symptoms cause insomnia,30 but the challenging question 
is whether both are contributing to a viscous circle and 
insomnia making respiratory symptoms like in asthma 
more pronounced. Awakening from sleep is associated 
with increased sympathetic activity and that can in turn 
cause airway inflammation, wheezing and coughing.30 
Studies assessing the possible effect of interventions for 
comorbid insomnia among patients with respiratory 
symptoms (medications and/or cognitive behavioural 
therapy) might theoretically improve the clinical condi-
tions among such patients.
To summarise, our results show a large geographical 
variation between different subtypes of insomnia. Symp-
toms of insomnia are related to respiratory symptoms and 
isolated initial insomnia is associated with lower FEV1. 
Whether improvement in insomnia affect respiratory 
health or whether treatment of respiratory symptoms 
affect insomnia is still to be investigated.
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